Solid Biosciences Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows the company's leadership and that it plans to issue more stock for future needs.
The company is selling shares to raise money, which dilutes existing shareholders but funds operations.
Quarterly earnings reveal if the company is making progress toward its goals and managing cash.
Directors balance board composition; this change means Ganot won't face re-election until 2028.
Large stock registration means the company may sell many shares soon to raise capital.
Smaller stock registration for selling stockholders; part of broader fundraising efforts.
Annual earnings show the company's full-year performance, cash position, and research progress.
Stocky reads Solid Biosciences Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Solid Biosciences Inc.'s most recent tracked filing was a 8-K on 10 Jun 2026: Stockholders elect three directors and double authorized shares.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.